Latest News
TRK Fusions Found in Some GIST Cases Without KIT/PDGFRA Mutations
Hand-Assisted Laparoscopic Surgery Benefits Gastric GIST
FDA Grants Orphan Drug Designation to Ilixadencel for GIST
Three Years of Adjuvant Imatinib Tolerable and Effective for GIST, Study Finds
Olverembatinib Shows Therapeutic Potential in GIST
Pimitespib Improves Progression-Free Survival in Advanced GIST Study
SMYD2 Accelerates Disease Progression in GIST
Neoadjuvant Imatinib Useful for Minimally Invasive GIST Resection
Imatinib for Rectal GISTs Improves Outcomes, Study Finds
Latest Clinical Trials
Insights
Beyond Imatinib: Next-Generation TKIs for the Treatment of GIST
Recently developed TKIs such as ripretinib and avapritinib have the potential to change the treatment landscape of GIST.
Diagnosing GIST Preoperatively: Challenges and Advantages
Various studies have analyzed how to better diagnose gastrointestinal stromal tumors at the preoperative stage.
Should Imatinib Be Discontinued in Patients With Advanced GIST?
We explore how imatinib became the first-line therapy for metastatic GIST, and whether it should be discontinued in some circumstances.
Targeting the PDGF/PDGFR Pathway in Cancer Research
We discuss current therapeutic strategies in targeting the PDGF/PDGFR signaling pathway in cancer research.
Patient Perspectives
A GIST Patient’s Journey: A Quest to be Heard
When diagnosed with a gastrointestinal stromal tumor (GIST) or any rare disease, the patient usually sees a doctor specializing in the treatment of that disease. Unfortunately, I live on a rock in the middle of the ocean, which makes finding the right doctor especially difficult.
Help GIST Patients Find Their New Normal
Many cancer patients would disagree, but GIST cancer has been both the best and worst thing that has ever happened to me.
A Frontline View: A Clinical Trial For Pediatric and Wildtype (SDHA) GIST
Three years ago, I heard one of the many things a cancer patient does not want to hear, “You have new growths. You’ve relapsed.” It was the first time I cried because of my cancer diagnosis, reality finally hit, and I was devastated. Relapsing with pediatric and wildtype (SDHA) gastrointestinal stromal tumor (GIST) was hard…
GIST Features
Using Deep Learning to Predict Risk in Gastrointestinal Stromal Tumors
Deep learning is now used to detect disease or abnormalities from x-ray images and classify them into several disease types or severities in radiology.
New Advances in the Radiomics of Gastrointestinal Stromal Tumors
It has been shown that radiomic features may be useful for predicting patient survival, treatment response, and metastatic potential of tumors.
Israel Emerges as Global Powerhouse in Rare Disease Research
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards
Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses.
Rare Care Podcast
Advocating for People With Gastrointestinal Stromal Tumor: An interview with Peter Knox, senior research director at the Life Raft Group
- Loading...
Loading...
Loading... 
Loading...